Markets:

Overview

News

Currencies

International

Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

22.65 -3.83 (-14.46%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Denali Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations

October 03, 2022

From Denali Therapeutics Inc.

Via GlobeNewswire

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗

September 29, 2022

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...

Via Benzinga

Netflix, Biogen And Other Big Gainers From Wednesday ↗

September 29, 2022

U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session ↗

September 28, 2022

Gainers

Via Benzinga

R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions

June 29, 2022

Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the...

Via FinancialNewsMedia

Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics

June 07, 2022

Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still...

Via FinancialNewsMedia

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗

June 23, 2022

Upgrades

Via Benzinga

Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026

June 22, 2022

Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It...

Via FinancialNewsMedia

4 Undervalued Biotech Stocks to Add to Your Buy List ↗

April 20, 2022

These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.

Via InvestorPlace

AbbVie Stock Breaks Its Stride As Key Executive Departs For Flagship ↗

April 13, 2022

Flagship Pioneering is swiping one of AbbVie's biggest names.

Via Investor's Business Daily

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development

March 31, 2022

Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia...

Via FinancialNewsMedia

7 F-Rated Stocks to Avoid During the Downturn ↗

March 23, 2022

It's easy to find hard hit stocks in this market, but what's harder to determine is which stocks are truly F-rated stocks among the losers.

Via InvestorPlace

Denali Receives Formal Letter Regarding FDA Hold On Alzheimer's Potential Program ↗

February 14, 2022

As previously announced, Denali Therapeutics Inc (NASDAQ: DNLI) was informed via e-mail communication from the FDA that DNL919 (ATV:TREM2) Investigational New Drug (IND...

Via Benzinga

The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly ↗

February 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

48 Biggest Movers From Yesterday ↗

January 14, 2022

Gainers Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday. MedAvail Holdings, Inc (NASDAQ: MDVL) gained 24.4% to settle at $1.58...

Via Benzinga

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

January 13, 2022

Gainers Rockwell Medical (NASDAQ:RMTI) st...

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Dips 250 Points; Taiwan Semiconductor Shares Gain ↗

January 13, 2022

Toward the end of trading Thursday, the Dow traded up 0.03% to 36,301.73 while the NASDAQ fell 1.67% to 14,934.36. The S&P also fell, dropping, 0.77% to 4,689.96. The U.S. has...

Via Benzinga

Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure ↗

January 13, 2022

Denali Therapeutics is under pressure after the FDA put its study on hold.

Via Investor's Business Daily

26 Stocks Moving In Thursday's Mid-Day Session ↗

January 13, 2022

Gainers Dave Inc. (NASDAQ: DAVE) gained 29.4% to $6.73. Takung Art Co., Ltd. (NASDAQ: TKAT) shares gained 18.6% to $4.1499. Traders are circulating earlier news that China is...

Via Benzinga

Mid-Morning Market Update: Markets Rise; Delta Air Lines Profit Tops Estimates ↗

January 13, 2022

Following the market opening Thursday, the Dow traded up 0.37% to 36,423.44 while the NASDAQ rose 0.12% to 15,206.73. The S&P also rose, gaining, 0.21% to 4,736.11. The U.S....

Via Benzinga

FDA Places Clinical Hold On Denali's Alzheimer's Potential Program ↗

January 13, 2022

The FDA has issued a clinical hold on Denali Therapeutics Inc's (NASDAQ: DNLI) Investigational New Drug (IND) application for DNL919 (ATV:TREM2). TREM2 is...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 13, 2022

Gainers iSpecimen (NASDAQ:ISPC) shares rose 19.8% to $8.18 during Thursday's pre-market session. The market value of their outstanding shares is at $71.4 million. VYNE...

Via Benzinga

Jim Cramer Says This Stock Is 'Really Cheap' ↗

December 16, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Academy Sports and Outdoors (NYSE:

Via Benzinga

Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression

November 23, 2021

Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market....

Via FinancialNewsMedia

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

Denali Highlights Encouraging Early Data, Update For Amyotrophic Lateral Sclerosis Program ↗

October 07, 2021

Denali Therapeutics Inc (NASDAQ: DNLI) announced data from the Phase 1 trial evaluating DNL343, eIF2B activator, in 95 healthy volunteers. DNL343 was generally...

Via Benzinga

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More ↗

October 03, 2021

Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.